1. Bennett N, Dodd T, Flatley J, Freeth S, Bolling K. Health Survey for England 1993. (HMSO, London 1995).

2. Barker DJP. Fetal origins of coronary heart disease. British Medical Journal 311:171-4, 1995.

3. Barker DJP et al. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. British Medical Journal 298:654-7, 1989.

4. Hales CN et al. Fetal and infant growth and impaired glucose tolerance at age 64. British Medical Journal 303:1019-22, 1991.

5. Kolterman OG, Insel J, Sackow M & Olefsky M. Mechanisms of insulin resistance in human obesity. Journal of Clinical Investigation 65:1272-1284,1980.

6. Reynisdottir S, Ellerfeldt K, Wahrenberg H, Lithell H, Arner P. Multiple lipolysis defects in insulin resistance [metabolic] syndrome. Journal of Clinical Investigation 93:2590-9, 1994.

7. Lonnquist F, Thorne A, Nilsell K, Hoffstedt J, Arner P. A pathogenic role of visceral fat b3-adrenoceptors in obesity. Journal of Clinical Investigation 95:1109-16, 1995.

8. Frayn , Williams CM, Arner P. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Clinical Science 90:243-253, 1996.

9. Sniderman A, Cainflone K. Metabolic disruptions in the adipocyte-hepatocyte fatty acid axis as the cause of hyperapoB. International Journal of Obesity19[suppl 1]:S27-33, 1995.

10. Colditz GA, Willett WC, Rotnitsky A, Manson JE. Weight gain as a risk factor for clinical diabetes in women. Archives of Internal Medicine 122:481-6, 1995.

11. Chan JM et al. Obesity, fat distribution and weight gain as riskfactors for clinical diabetes in men. Diabetes Care 17:961-9, 1994.

12. Lean MEJ, Hans TS, Seidell JC. Impairment of health and quality life in people with large waist circumference. Lancet 351:853-6, 1998.

13. Reaven GM. Banting Lecture 1988. Role of insulin in human disease. Diabetes 37:1595-1607, 1988.

14. Lapidus L, Bengtsson C, Larsson B, Pennart K, Rybo E & Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. British Medical Journal 289:1257-1261,1984

15. Larsson B, Svardsudd K, Welin L, Wilhelmsen l, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. British Medical Journal 288:1401-1404, 1984

16. Masserli FH et al. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation 66:55-60, 1982.

17. De Divitiis O et al. Obesity and cardiac function. Circulation 64:477-82, 1981.

18. Licata G et al. Effect of obesity on left ventricular function studied by radionuclide angiography. International Journal of Obesity 15:295-302, 1991.

19. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. Journal of the American Medical Association 266:231-6, 1991.

20. de la Maza M et al. Ventricular mass in hypertensive and normotensive obese subjects. International Journal of Obesity 18:193-7, 1994.

21. Garavaglia GE et al. Myocardial contractility and left ventricular function in obese patients with essential hypertension. American Journal of Cardiology 62:594-7, 1988.

22. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation 67:968-77, 1983.

23. Willet WC et al. Weight, weight change and coronary heart disease in women. Journal of the American Medical Association 273:461-5, 1995.

24. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the haemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscelrosis Thrombosis 13:1865-73, 1993.

25. Eriksson P, Renisdottir S, Lonnqvist F et al. Adipose tissue secretion of plasminogen activator-1 in non-obese and obese individuals. Diabetologia 41:65-71, 1998.

26. Kooistra T, Bosma P, Tons H et al. Plasminogen activator-1:biosynthesis and mRNA levels are increased by insulin in cultured hepatocytes. Thrombosis Haemostasis 62:723-8, 1989.

27. Shimomura I, Funahashi T, Takahashi M et al. Enhanced expression of PAI-1 in visceral fat: a possible contributor to vascular disease in obesity. Nature Medicine 7:800-3, 1996

28. Juhan-Vague I, Pyke SDM, Alessi MC et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 94:2057-63., 1996.

29. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Annals of Internal Medicine 118:956-63, 1993.

30. Kannel WB, Wolf PA, Castelli WP, d'Agostino RB. Fibrinogen and the risk of cardiovascular disease: The Framingham Study. Journal of the American Medical Association 258:1183-6, 1997.

31. Woodward M, Lowe GDO, Rumley A. Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. British Journal of Haematology 97:785-97, 1997

32. Kopelman PG. Sleep apnoea and hypoventilation in obesity. International Journal of Obesity 16(suppl 2):S37-S42, 1992.

33. Grunstein RR. Pulmonary function, sleep apnoea and obesity. In: Clinical Obesity (eds. Kopelman PG, Stock MJ) 248-89 (Blackwell Science, Oxford 1998).

34. Kopelman PG, Apps MCP, Cope T, Empey DW. Nocturnal hypoxia and sleep apnoea in asymptomatic men. International Journal of Obesity 10:211-17, 1986.

35. Kopelman PG, Apps MCP, Cope T, Empey DW. The influence of menstrual status, body weight and hypothalamic function on nocturnal respiration in women. Journal of the Royal College of Physicians of London 19:243-7, 1985.

36. Rochester DF, Eaton Y. Current concepts in the pathogenesis of the obesity-hypoventilation syndrome. Mechanical and circulatory factors. American Journal of Medicine 57:402-20, 1974.

37. Grunstein RR, Stenlof K, Hedner J, Sjostrom L. Impact of obstructive apnoea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study. International Journal of Obesity 19:410-18, 1995.

38. Palomaki H, Partinen M, Erkinjuntti T, Kaste M. Snoring, sleep apnoea syndrome and stroke. Neurology 42(suppl6):75-81, 1992.

39. Marin P, Lonn L, Andersson B, et al. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissue in vivo in men. J Clin 1996;81:1018-1022.

40. Dunaif A. Polycystic ovary syndrome and obesity. In: Bjorntorp P, Brodoff PN., eds. Obesity, Philadelphia: Lippincott, 594-605, 1992.

41. Kopelman PG. Neuroendocrine function in obesity. Clinical Endocrinology 28:675-689, 1998.

42. Longcope C, Kato T, orton R. Conversion of blood androgens to estrogens in normal adult men and women. J Clin Invest 48:2191-2201, 1969.

43. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 72:1150-1162, 1983.

44. Bacon BR, Farahvash MJ, Janney CG, Neushwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107:1103-09, 1994.

45. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 353:1634-6, 1999.

46. Caldwell SH, Oelsner DH, Lezzoni JC, Hessenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterisation and risk factors for underlying disease. Hepatology 29:664-69, 1999.

47. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12:1106-10, 1990.

48. Andersen T, Gluud C, Franzmann M, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. Journal of Hepatology 12:224-29, 1991.

49. Stampfer MJ, Maclure MK, Colditz GA, Manson JE, Willett WC. Risk of symptomatic gallstones in women with severe obesity. American Journal of Clinical Nutrition 55:652-658, 1992.

50. Festi D, Colecchia A, Orsini M, Sangermano A, Sottili S, Simoni P, Mazzella G et al. Gallbladder motility and gallstone formation in obese patients following very low calorie diets. Use it (fat) to lose it (well). International Journal of Obesity 22:592-600, 1998.

51. Lew EA, Garfinkel L. Variations in mortality among 750,000 men and women. Journal of Chronic Disease 32:563-76, 1979.

52. Goodman MT, Morgenstern H, Wynder EL. A case-control study of factors affecting the development of renal cell carcinoma. American Journal of Epidemiology. 124:926-941, 1986.

53. Le Marchand L, Kolonel L, Earle M, Mi M. Body size at different periods of life and breast cancer risk. American Journal of Epidemiology 1287:137-152, 1988

54. Bruning P, Bonfrer J, Hart A et al. Body measurement, oestrogen availability and the risk of human breast cancer: a case control study. International Journal of Cancer 51:14-19, 1992.

55. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of health care. Annals of Rheumatic Diseases 60:91-7, 2001.

56. Sharma L, Song J, Felson D, Cahue S, Shamiyeh E, Dunlop DD. The mechanism of the effect of obesity in knee osteoarthritis. Arthritis Rheum 43:568-75, 2000.

57. Barsh GS, Farooqi IS, O'Rahilly S (2000). Genetics of body weight regulation: applications and opportunities. Nature 404:644-51, 2000.